###### Strengths and limitations of this study

-   The study included a relatively large number of women from high-volume facilities in all study groups, allowing us to detect differences between the time periods.

-   As the study assessed only one primary care centre in the first 2 years after decentralisation, we were unable ascertain the intervention's long-term sustainability, or to assess the impact of a broader decentralisation strategy, such as a hub and spoke approach encompassing several primary care centres.

-   A hub and spoke approach has been successfully applied to other similar health services that require an integrated, tiered healthcare and laboratory system (such as Tuberculosis (TB) care and colorectal cancer screening), supporting the generalisability of the study findings to similar settings and assertions about the validity of the results reported.

-   The limited number of variables collected meant that the study could not investigate several important questions in detail, such as reasons for delays in colposcopy, the quality of decentralised services or comparisons of changes in access among women at the primary care site over time.

-   Data were collected for the purposes of patient care, and not specifically for research, potentially reducing data quality.

Introduction {#s1}
============

Cervical cancer is a largely preventable disease and WHO has recently launched an initiative aimed at eliminating the condition.[@R1] At present, cervical cancer is the second most common cancer among women aged 15--44 years in the world.[@R2] In South Africa, it is the most common cancer in that age group, and mortality rates are high.[@R3] About 3% of women in South Africa harbour cervical human papilloma virus (HPV)-16/18, which is responsible for the majority of cases of cervical cancer in the country.[@R4] Rates of cervical cancer in South Africa can partly be attributed to the high level of HIV.[@R5] Women with HIV infection have a sevenfold higher rate of persistence of high-risk HPV compared with HIV uninfected women,[@R6] heightening their risk for incident and progressive precancerous lesions. While antiretroviral therapy reduces the risk of cervical cancer and its precursors, the risk remains much higher than for HIV-negative women.[@R7]

In South Africa, the policy for cervical cancer screening was introduced in 2001 and updated in 2017.[@R8] The policy recommends that low-risk women have three Papanikolaou (Pap) smears in a lifetime at the ages of 30, 40 and 50 years, while women with HIV infection are to be screened every 3 years, regardless of age. About 60% of women aged 30--49 years have had cervical cancer screening.[@R9] Screening is predominately based on cytology using Pap smears, although there are plans to introduce liquid-based cytology which offers the potential to do HPV screening. Women with atypical findings on cytology are referred for colposcopy to establish a definitive diagnosis. During colposcopy, the view of the cervix is magnified and, where required, a biopsy is taken or a large loop excision of the transformation zone (Lletz) is conducted.[@R10]

The gap between screening for cervical cancer and treatment of high-risk lesions is believed to be very high in South Africa.[@R11] Although there are few published data to support this assertion, the fact that the number of cervical cancer cases remains high despite the large number of cervical cancer screening procedures suggest this is the case. A range of health systems and patient factors influence access to colposcopy. System barriers include a limited number of colposcopy services, which are mostly centralised within tertiary-level facilities, with long waiting times for patients and few opportunities for non-specialist health workers to develop requisite skills.[@R12] There are limited numbers of specialist gynaecologists within the public sector, and the high demands on these doctors for emergency and curative obstetric and gynaecology services may reduce their time available for diagnostic or preventive interventions, such as colposcopy. Another key factor is the complexity of providing Pap and other results to patients and then scheduling colposcopy appointments across the disjointed systems that often exist between a tertiary hospital and primary care centres.[@R13] Patient-related factors linked with low uptake of colposcopy include low education levels, being single, fear of HIV testing and disclosure, a low CD4 count in HIV-infected women and transport costs for the additional visits.[@R14] Patient demand for colposcopy is also undermined by a general fear of cancer, and lack of awareness or knowledge about cervical cancer.[@R13] Poor patient--provider interactions restrict access, while a long-standing relationship with a primary clinician can optimise uptake.[@R18]

In South Africa, colposcopy procedures are generally done at tertiary-level facility, by specialist gynaecology oncologists and trainee gynaecologists under supervision. While there may be benefits to decentralising colposcopy services to lower levels of care, these need to be balanced by the advantages of centralisation of cancer services, such as concentrating clinical expertise, with a higher quality of care, and the rationalisation of expensive specialist equipment. Thus, in this before and after study, we aimed to determine if access to colposcopy increased following the decentralisation of colposcopy services from a tertiary-level hospital to a primary care facility in inner-city Johannesburg, South Africa. We compare the total number of colposcopies done and the coverage of colposcopy services in the primary-level facility after decentralisation. We also compare the two sites, specifically, the patient profile and cervical cancer risks, colposcopy procedures, quality of the services and histology outcomes.

Methods {#s2}
=======

Study participants and setting {#s2a}
------------------------------

Women, aged 18 years and older, who accessed colposcopy services at either Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) or Hillbrow Community Health Centre (HCHC) between October 2012 and September 2016 were included in the study. Both facilities are in subdistrict F of the Johannesburg Health District (JHD).

The colposcopy clinic at CMJAH is part of the Gynaecology-Oncology Department at CMJAH, which has two colposcopy machines. Women attending a facility in JHD who have an abnormal Pap smear are referred to the facility, where they are provided with an appointment date for colposcopy.

HCHC is situated in the densely populated inner-city area of Hillbrow, about 3 km from CMJAH.[@R19] HCHC provides primary-level care, including a 24-hour casualty and a midwife obstetrics unit. The facility is run predominantly by nursing staff, with support from non-specialist medical doctors.

Implementation of decentralised services {#s2b}
----------------------------------------

In 2013, a review of patient files at HCHC found that a large proportion of women attending the HIV clinic had high-risk lesions on Pap smear.[@R20] Moreover, there were reports from patients and health workers at HCHC of prolonged waiting times for colposcopy services at CMJAH. The Wits Reproductive Health and HIV Institute thus set about establishing decentralised colposcopy services at HCHC. A private sector company donated a colposcopy machine. Two district medical officers were trained by specialist gynaecology oncologists at CMJAH to provide the service. CMJAH staff provided ongoing support and established referral processes between the two facilities. Monthly meetings were held between staff at the two facilities, where concerns and difficult cases could be discussed.

The services, which began in October 2014, were provided twice a week by the medical officers, with assistance from the nurse who takes Pap smears at the facility. Patients attending HCHC and some referred from surrounding clinics were given an appointment for colposcopy if they had an abnormal Pap smear result, defined as: high-grade squamous intraepithelial lesion (HSIL), atypical squamous cell and HSIL cannot be excluded or squamous cell carcinoma.[@R21] A few patients with Pap smear results other than those defined as abnormal smears were also referred for colposcopy. Patients with complex lesions, such as abnormal cervical anatomy or a high suspicion of cancer on Pap smear, were referred to CMJAH, as were those with a failed colposcopy. Colposcopy procedures included colposcopic assessment only, or colposcopic assessment together with either a Lletz or biopsy. Histology specimens were processed at the National Health Laboratory Service (NHLS).

Data sources and collection {#s2c}
---------------------------

For the purpose of this evaluation, women who accessed colposcopy services at CMJAH and HCHC were divided into three groups: (1) pre-decentralisation at CMJAH between October 2012 and September 2014, (2) post-decentralisation at CMJAH between October 2014 and September 2016 and (3) post-decentralisation at HCHC between October 2014 and September 2016.

At CMJAH, we extracted data from paper-based records at the colposcopy clinic, including on patients' age, HIV status, antiretroviral treatment, date of Pap smear, Pap smear result, date of colposcopy, colposcopy procedure performed and histology results. Data were entered into a REDCap electronic database (REDcap V.4.14.5, Vanderbilt University).[@R22] At HCHC, demographic and clinical data on women who accessed colposcopy services were entered into an MS Excel spreadsheet after each patient visit. Data were obtained from the NHLS on Pap smear cytology for women attending HCHC who had a Pap smear and for the whole of JHD.

Study variables and statistical analysis {#s2d}
----------------------------------------

Access to colposcopy was measured by the total number of colposcopies done across the two facilities and the colposcopy coverage at HCHC, the primary study outcome. Coverage was estimated by calculating the proportion of all women at HCHC with an abnormal Pap smear who had a colposcopy. Time to colposcopy was calculated as the number of months from date of Pap smear to colposcopy and was categorised as optimal (under 3 months), acceptable (3--6 months) and delayed (\>6 months). We also examined changes in referral patterns of women who had an abnormal Pap smear at HCHC.

Patient characteristics were compared between the three groups, as well as level of integration of HIV services (provision of HIV testing and antiretroviral treatment).

We also compared the types of colposcopy procedures performed in the different periods and histology findings. Histology results were classified as normal (includes benign endocervical polyp, atrophic ectocervical mucosa, koilocytotosis and metaplasia), cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III, carcinoma, other (includes infections such as cervicitis, inflammation and dysplasia) and invalid specimens (includes absent results). Quality of services was evaluated using proxy markers, specifically the proportion of invalid specimens and number of unsuccessful colposcopy procedures. Differences between the three study groups were assessed using a chi-square test or a Wilcoxon rank-sum test, as appropriate. All data were analysed using STATA V.13.0.

Patient and public involvement {#s2e}
------------------------------

The study utilised data that had already been collected as part of routine patient care, and thus patients were not directly involved in the study. We did, however, attempt to contact patients who had abnormal lesions on histology and had not attended follow-up visits.

Results {#s3}
=======

Access to colposcopy and timeliness of services {#s3a}
-----------------------------------------------

In total, 910 women accessed colposcopy at CMJAH between October 2012 and September 2014. In the subsequent 2 years, 1120 women had a colposcopy: 399 at HCHC (35.6%) and 721 at CMJAH (64.4%; [table 1](#T1){ref-type="table"} and [figure 1](#F1){ref-type="fig"}).

###### 

Patient characteristics and colposcopy outcomes at a community clinic (Hillbrow CHC), and a tertiary-level facility (CMJAH) before and after decentralisation

  Variables                        Before versus after decentralisation at CMJAH   HCHC versus CMJAH after decentralisation                              
  -------------------------------- ----------------------------------------------- ------------------------------------------ --------- ---------------- ---------
  Characteristics                                                                                                                                        
   Age groups in years                                                                                                                                   
    \<20                           7 (0.8)                                         6 (0.8)                                                               
    20--34                         351 (39.8)                                      209 (30.2)                                           150 (37.6)       
    35--44                         342 (38.8)                                      266 (38.4)                                           156 (39.1)       
    45--59                         161 (18.3)                                      187 (27.0)                                           79 (19.8)        
    \>60                           20 (2.3)                                        25 (3.6)                                   0.001     7 (1.8)          0.003
   HIV status known                650 (71.4)                                      429 (59.5)                                 \<0.001   399 (100)        \<0.001
   HIV status\*                                                                                                                                          
    Negative                       105 (16.2)                                      59 (13.8)                                            62 (15.5)        
    Positive                       545 (83.9)                                      370 (86.3)                                 0.28      337 (84.5)       0.47
   On ART†                         428/544 (78.7)                                  324/370 (87.6)                             \<0.001   336/337 (99.7)   \<0.001
  Cervical cancer screening                                                                                                                              
   Facility where Pap smear done                                                                                                                         
    CMJAH                          115 (12.8)                                      124 (17.5)                                           0 (0.0)          
    HCHC                           114 (12.7)                                      43 (6.1)                                             307 (76.9)       
    Other clinic or hospita**l**   671 (74.6)                                      540 (76.4)                                 \<0.001   92 (23.1)        \<0.001
   Pap smear results                                                                                                                                     
    NILM                           6 (0.7)                                         8 (1.1)                                              17 (4.3)         
    LSIL                           141 (15.5)                                      125 (17.4)                                           79 (20.0)        
    ASCUS                          19 (2.1)                                        34 (4.7)                                             4 (1.0)          
    HSIL                           678 (74.7)                                      478 (66.4)                                           263 (66.4)       
    ASC-H                          63 (6.9)                                        65 (9.0)                                             27 (6.8)         
    Carcinoma                      1 (0.1)                                         10 (1.4)                                   \<0.001   6 (1.5)          \<0.001
   Pap smear risk categories                                                                                                                             
    NILM, LSIL or ACSUS            166 (18.3)                                      167 (23.2)                                           100 (25.3)       
    HSIL, ASC-H or carcinoma       742 (81.7)                                      553 (76.8)                                 0.015     296 (74.8)       0.44
  Cervical cancer diagnosis                                                                                                                              
   Procedure during colposcopy                                                                                                                           
    Visual inspection only         37 (4.1)                                        37 (5.2)                                             63 (15.9)        
    Lletz                          337 (37.2)                                      258 (35.9)                                           231 (58.2)       
    Biopsy                         526 (58.0)                                      420 (58.4)                                           90 (22.7)        
    Other                          7 (0.8)                                         4 (0.6)                                    0.69      13 (3.3)         \<0.001
  Histology result‡                                                                                                                                      
    Normal                         27 (3.1)                                        30 (4.4)                                             45 (13.8)        
    CIN I                          254 (29.3)                                      200 (29.3)                                           84 (25.7)        
    CIN II                         298 (34.3)                                      209 (30.7)                                           99 (30.3)        
    CIN III                        236 (27.2)                                      198 (29.0)                                           86 (26.3)        
    Carcinoma                      3 (0.4)                                         9 (1.3)                                              2 (0.6)          
    Other§                         34 (3.9)                                        19 (2.8)                                             2 (0.6)          
    Invalid specimen               16 (1.8)                                        17 (2.5)                                   0.10      9 (2.8)          \<0.001

χ^2^ test for categorical variables or Wilcoxon rank-sum test for continuous variables.

\*Of those with a known HIV status.

†Of those HIV positive.

‡Of those with a histology specimen taken at biopsy, Lletz or other procedure.

§Other includes infections such as cervicitis, inflammation and dysplasia.

ASC-H, atypical squamous cell and HSIL cannot be excluded; ASCUS, Atypical squamous cell of uncertain significance; CIN, cervical intraepithelial neoplasia; CMJAH, Charlotte Maxeke Johannesburg Academic Hospital; HCHC, Hillbrow Community Health Centre; HSIL, high-grade squamous intraepithelial lesion; LSIL, Low-grade squamous intraepithelial lesion; NILM, Negative for intraepithelial lesion and malignancy; Pap, Papanikolaou.

![(A) Total number of colposcopies done before and after decentralisation. (B) Number of cervical intraepithelial neoplasia lesions detected before and after decentralisation. CIN, cervical intraepithelial neoplasia.](bmjopen-2018-024726f01){#F1}

Of all Pap smears done in the JHD in the 2 years after decentralisation (114 983), 1.9% were done at HCHC (2227; [table 2](#T2){ref-type="table"}). Overall, 18.0% of Pap smears done at HCHC had abnormal cytology and required colposcopy (n=401), compared with only 8.2% of other women in JHD as a whole (n=1826; p\<0.001). The estimated colposcopy coverage among women who had an abnormal Pap smear at HCHC was 66.6% (267/401; 95% CI 61.7% to 71.2%). The number of women who had a Pap smear at HCHC and then a colposcopy at either facility was threefold higher post-decentralisation than pre-decentralisation (from 113 to 350) ([table 1](#T1){ref-type="table"}).

###### 

Cytology results in the City of Johannesburg in 2014--2016

  Variable n (%)                   **J**ohannesburg health district\* (n=114 983)   Hillbrow Community Health Centre (n=2227)   P value
  -------------------------------- ------------------------------------------------ ------------------------------------------- ---------
  Pap smear results                                                                                                             
  NILM                             74 969 (65.2)                                    852 (38.3)                                  
  LSIL                             23 212 (20.2)                                    790 (35.5)                                  
  ASCUS                            7391 (6.4)                                       184 (8.3)                                   
  HSIL                             7808 (6.8)                                       364 (16.3)                                  
  ASC-H                            1221 (1.1)                                       28 (1.3)                                    
  Carcinoma                        382 (0.3)                                        9 (0.4)                                     \<0.001
  Number requiring colposcopy                                                                                                   
  No (NILM, LSIL or ASCUS)         105 572 (91.8)                                   9411 (82.0)                                 
  Yes (HSIL, ASC-H or carcinoma)   1826 (8.2)                                       401 (18.0)                                  \<0.001

Data from the National Health Laboratory Service. Excludes invalid or missing specimens, and other Pap smear results (n=2446).

\*District total excludes HCHC.

ASC-H, atypical squamous cell and HSIL cannot be excluded; ASCUS, Atypical squamous cell of uncertain significance; HSIL, high-grade squamous intraepithelial lesion; LSIL, Low-grade squamous intraepithelial lesion; NILM, Negative for intraepithelial lesion and malignancy; Pap, Papanikolaou.

Almost half of the women at CMJAH had a delay in receiving colposcopy (\>6 months between Pap smear and colposcopy) post-decentralisation, compared with about a third pre-decentralisation (47.3% vs 36.2%, p\<0.001; [figure 1A](#F1){ref-type="fig"}). At HCHC, 21.7% of women had a colposcopy within 3 months of a Pap smear being taken (vs 11.8% at CMJAH pre- and 15.4% post-decentralisation, p\<0.001).

The absolute number of women at CMJAH who had had a Pap smear at HCHC decreased from 113 to 43 in the second period. One-quarter of women who had a colposcopy at HCHC had had their Pap smear at another facility.

Characteristics of women in the three groups and HIV service integration {#s3b}
------------------------------------------------------------------------

The proportion of women older than 45 years pre-decentralisation at CMJAH was 20.6%, post-decentralisation at CMJAH 30.6% and at HCHC 21.9% (p\<0.001). At CMJAH, more women had a known HIV status pre-decentralisation than post-decentralisation (71.4% vs 59.5%, p\<0.001). All women at HCHC had a documented HIV status. Around 85% of women with a known HIV status were HIV positive in all three groups. The proportion of positive women receiving antiretroviral therapy (ART) rose in the second period at CMJAH from 78.7% to 87.6% (p\<0.001), and almost all positive women were on ART at HCHC (99.7%; p\<0.001) ([table 1](#T1){ref-type="table"}).

Description of colposcopy procedures, histology findings and colposcopy quality {#s3c}
-------------------------------------------------------------------------------

At CMJAH, in both periods, \~60% of women had a biopsy at colposcopy (58.2%), while the same proportion had a Lletz at HCHC (58.2%). Three women who had a colposcopy at HCHC were referred to CMJAH due to an unsuccessful procedure.

Women at HCHC were 3.5-fold more likely to have a normal result on histology than women at CMJAH (95% CI:2.1--5.7). Post-decentralisation, 29.0% of women at CMJAH and 26.3% at HCHC had CIN III lesions (p=0.37; [figure 1B](#F1){ref-type="fig"}). Post-decentralisation, 11 women had a diagnosis of carcinoma on histology (1.1%), compared with 3 before decentralisation (0.4%; p=0.06). The proportion of invalid specimens was similar across the three groups, ranging from 1.8% to 2.8% ([table 1](#T1){ref-type="table"}).

Discussion {#s4}
==========

In this study, we determined whether decentralisation to primary care level improved access to colposcopy services by reviewing the number of women attending the service before and after decentralisation, and the coverage of colposcopy among women at HCHC. We found that the cumulative number of colposcopies across the two facilities rose following decentralisation, and after only 2 years, HCHC was responsible for a third of all colposcopies in the subdistrict, even though it performs a negligible number of Pap smears relative to other sites. Overall, following decentralisation, threefold more women who had a Pap smear at HCHC had a colposcopy, and equally, at CMJAH, the proportion of women referred from HCHC reduced almost threefold. The marked increase in number of women from HCHC who had a colposcopy indicates that prior to decentralisation there may have been a large unmet need for the service, which was now being addressed, at least in part. The coverage reached 66.6%, considerably higher than figures in other settings.

Decentralisation of colposcopy services to primary-level care has several potential benefits. First, with adequate training, tasks that had been performed by highly specialised staff can be shifted to lower health worker cadres, allowing specialists to focus on more complex cases.[@R23] Additionally, decentralisation may alleviate patient barriers to access, by bringing services closer to them---in settings they are familiar with---and reducing their transport and other costs.[@R13] Decentralisation has long been central to the provision of HIV services in this setting through, for example, task shifting, providing antiretroviral treatment in primary care services and the dispensing of drugs from local pharmacies, rather than clinics.[@R24]

Decentralisation of colposcopy can take several forms, including telecolposcopy from distant sites, outreach portable colposcopy, shifting of services to nurse practitioners or medical officers and decentralisation to lower-level facilities, as in this study.[@R25] In other settings, shifting services to lower care levels was found to be cost-effective, acceptable to patients and to increase rates of attendance for colposcopy.[@R16] In the Western Cape, South Africa, for example, colposcopy services were decentralised to a district hospital and provided by a gynaecologist.[@R23] This raised uptake of the service and reduced time to procedure. In high-income countries, services have been successfully decentralised to community health centres and portable outreach programmes in Alaska, the USA, and parts of Canada and Australia, targeting immigrant, Inuit and other vulnerable women.[@R16] The National Health Service in UK has gone a step further and colposcopy is often performed by nurse practitioners once they have completed certification procedures.[@R29]

Women attending HCHC colposcopy were at lower risk than those at CMJAH, as shown by their lower grades of abnormalities on Pap smear and histology. Women at HCHC were also younger than those at CMJAH, important as risk for cervical cancer is higher in rises considerably with age (the mean age at diagnosis of cervical cancer is 52.3 in South Africa).[@R30] These findings may suggest that, as the programme had envisaged, higher-risk patients are being referred to CMJAH. Overall, services at HCHC appear to be performing well, with all women tested for HIV and almost all those positive were receiving ART. In addition, colposcopy services were now integrated into their care, which was previously off-site, complex to access and marked by lengthy delays. HIV-positive women made up the large majority of patients in all groups, reflecting the higher levels of risk for cervical cancer in this population. Clearly, it remains a priority to integrate screening for cervical cancer within all clinics providing antiretroviral treatment. Equally, ART and services such as screening and treatment for sexually transmitted infections could be integrated within colposcopy clinics, reducing the opportunity costs associated with multiple visits to the clinic and lowering the risk of loss to follow-up.

The similar number of invalid histology samples and the isolated cases of failed colposcopy suggests that the quality of colposcopy services at HCHC may have been comparable to CMJAH. Unlike at CMJAH, however, Lletz was the most common procedure at HCHC, in keeping with evidence that Lletz is better suited to lower-level facilities and staff.[@R10] With decentralisation, it is critical to ensure that staff are adequately trained and service quality is closely monitored. The hesitancy to decentralise colposcopy to date, may reflect underlying concerns that cases of cancer may go undetected by lower-level staff. In some settings, lower-level health workers undergo a process of certification and have to perform a certain number of colposcopies per year to remain registered.[@R29] While this approach may hold advantages, onerous processes around certification and recertification may lead to staff discontinuing colposcopy.[@R31]

The decline in number of colposcopies at CMJAH is concerning, and may reflect factors other than a reduction in demand that accompanies decentralisation. Fewer women at the site had a known HIV status and waiting times for colposcopy lengthened. Thus, though decentralisation can reduce the patient burden at referral centres, this does not necessarily translate into improved services at that site. Other factors may play a larger influence, for example, coinciding with the period after decentralisation, CMJAH lost a number of senior specialists.

Delays in colposcopy vary considerably between settings, from an average of 39 days from referral to colposcopy in one study in KwaZulu Natal, South Africa,[@R12] to around 5--6 months in both our study and another in the Western Cape.[@R23] It is concerning that time from Pap smear to colposcopy is \>6 months for half the women at CMJAH, and a third at HCHC. Reducing these delays is clearly a priority at both sites. We were unable, however, to discern reasons for these delays, which could be caused by delays in providing the results of Pap smears to patients, patient delays in making or attending appointments, or shortages of specialist staff. We could also not investigate which group of patients required referral to higher levels of care, and future studies might attempt to define criteria for referral. Moreover, given the relatively short period of the review, we are unable to assess sustainability of the services in the long-run, a pressing question. Lastly, the study evaluated the use of colposcopy following cytological screening with Pap smears and these findings may not be generalisable to screening with HPV testing.[@R29] HPV testing has a considerably higher sensitivity for detecting precursor lesions of cervical cancer compared with cytology, and thus may alter the number of patients requiring colposcopy and types of lesions identified.[@R32]

Conclusion {#s5}
==========

In conclusion, decentralisation of colposcopy services can improve access to colposcopy, resulting in faster diagnoses of precancerous lesions of the cervix, more lesions being treated with Lletz and a reduction in the burden of patients in tertiary hospitals. Most importantly, increasing the number of colposcopies and treatments of precancerous lesions could reduce the incidence of cervical cancer. This is particularly important among HIV-positive women who now live longer with ART, and the treatment of their co-morbidities is rapidly gaining in importance. Though coverage of colposcopy reached two-thirds at HCHC, it is important to identify interventions to further raise coverage levels. Decentralisation is unlikely to affect the quality of services if medical officers are appropriately trained, supervised and supported by clear referral guidelines. The approach presented here could be extended to other similar primary-level or secondary-level facilities in South Africa, and perhaps encompass the use of portable colposcopes or telecolposcopy, under close supervision. If done correctly and at scale, decentralisation of colposcopy services, could shore up cervical cancer prevention and finally decrease the public health burden and mortality due to the cancer.
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